Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 Phase 3 Results
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued […]
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued […]
Key Takeaways For facial vitiligo, pimecrolimus 1% shows superiority over placebo on F-VASI and global assessments in several RCTs/split-face designs.
Key Takeaways Facial/neck lesions show the highest response rates to tacrolimus 0.1%, often with early perifollicular islands of repigmentation. Trunk/extremities
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many
Key Takeaways Excimer 308 nm is well suited for localized/focal lesions, particularly on the face and neck, enabling targeted high-fluence delivery
Key Takeaways NB-UVB achieves comparable or superior facial repigmentation versus PUVA in multiple comparative studies, with fewer systemic adverse effects.
Key Takeaways NB-UVB (311–313 nm) consistently induces clinically meaningful repigmentation across multiple cohorts; face responds best, acral sites worst. Typical regimens
Key Takeaways Vitiligo imposes a clinically meaningful quality-of-life (QoL) burden; facial and visible-area involvement, rapid progression, and darker phototypes are
Key Takeaways Clinical diagnosis is usually sufficient; bedside confirmation relies on sharply demarcated depigmentation and accentuation under Wood’s lamp. Dermoscopy